Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sivelestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE known ✓ | P08246 | 16/20 | 0.71 |
| ▸ | PRTN3 | P24158 | 12/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sivelestat SCHEMBL4411781 | 1.00 | ELANE (0.71) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL28751433 | 1.00 | ELANE (0.71) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL566914 | 0.99 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL6690886 | 0.99 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL30864380 | 0.99 | ELANE (0.69) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL1499929 | 0.98 | ELANE (0.68) | ELANEPRTN3NPC1RAB9AKDM4E | |
| Sivelestat SCHEMBL597819 | 0.98 | ELANE (0.68) | ELANEPRTN3NPC1RAB9AKDM4E | |
| SCHEMBL7267891 | 0.92 | ELANE (0.71) | ELANEPRTN3KDM4EGAAHSD17B10 | |
| SCHEMBL9777074 | 0.91 | ELANE (0.69) | ELANEPRTN3NPC1KDM4EGAA | |
| Sivelestat SCHEMBL4411778 | 0.91 | ELANE (0.69) | ELANEPRTN3NPC1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1890 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12605455-B2 | CAR peptide for improved coronavirus survival | VASCULAR BIOSCIENCES (US) | 2026-04-21 | — | — | US | claimed |
| US-20260076936-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION OF SIVELESTAT OR SALT THEREOF AND PREPARATION METHOD THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2026-03-19 | — | — | US | claimed |
| EP-4648778-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | National Health Research Institutes (TW) | 2025-11-19 | — | — | EP | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | claimed |
| EP-4551207-A1 | METHOD FOR TREATING COCAINE ADDICTION | Pharwar Biotechnology, Inc. Pte. Ltd. (SG) | 2025-05-14 | — | — | EP | claimed |
| WO-2025049724-A1 | COMPOSITIONS AND METHODS FOR TREATING PLEURAL SPACE INFECTIONS AND HEMOTHORAX | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250064891-A1 | HOST PROTEASES ESSENTIAL FOR PARAINFLUENZA SPREAD IN THE HUMAN LUNG: POTENTIAL TARGETS FOR ANTIVIRAL INTERVENTIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-02-27 | — | — | US | claimed |
| WO-2006028586-A2 | BIOMARKERS AND THERAPEUTIC TARGETS FOR COGNITIVE DECLINE | DUKE UNIVERSITY (US) | 2006-03-16 | — | — | WO | claimed |
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | claimed |
| CN-1457772-A | Injection for curing acute lung injury and acute respirotary distress syndrome | HONGYI SCIENCE AND TECHNOLOGY (CN) | 2003-11-26 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| US-20020198138-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2002-12-26 | — | — | US | claimed |
| US-5403850-A | Elastase inhibitors, respiratory system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-04-04 | — | — | US | claimed |
| EP-0347168-B1 | DERIVATIVES OF P-SUBSTITUTED PHENYL ESTER OF PIVALIC ACID | ONO PHARMACEUTICAL CO (JP) | 1993-09-01 | — | — | EP | claimed |
| EP-0539223-A1 | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-28 | — | — | EP | claimed |
| EP-0347168-A1 | Derivatives of p-substituted phenyl ester of pivalic acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | ELANE 65/4885PRTN3 442/4885NPC1 4025/4885 |
| US-20020198138-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, MPO | ELANE 2/4885PRTN3 9/4885NPC1 1868/4885 |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | ELANE 2/4885PRTN3 30/4885NPC1 3197/4885 |
| US-20260076936-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION OF SIVELESTAT OR SALT THEREOF AND PREPARATION METHOD THEREOF | SERPINB1, ELANE, PLA2G2D | ELANE 2/4885PRTN3 393/4885NPC1 1642/4885 |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, SPINT2 | ELANE 2/4885PRTN3 17/4885NPC1 2113/4885 |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | ELANE 3976/4885PRTN3 3935/4885NPC1 630/4885 |
| US-12605455-B2 | CAR peptide for improved coronavirus survival | TMPRSS2, SARS1, ACE2 | ELANE 191/4885PRTN3 1085/4885NPC1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.